Comparison of first-line immunotherapy combinations for advanced kidney cancer

In this paper, three clinical trials with immunotherapy combinations for the first-line treatment of clear renal cell carcinoma (RCC) are discussed. Dr  Robert Motzer from Memorial Sloan Kettering Cancer Center in New York compared the findings from the three trials at the Annual Chemotherapy Foundation Symposium (CFS) in New York last week. All three phase […]

read more

The effect of antibiotic use on outcomes with kidney cancer drug treatments

A recent study has looked at the use of antibiotics with systemic drug treatments for renal cell carcinoma (RCC). The study investigated patients taking immune checkpoint inhibitors (146 patients), interferon-α (510 patients), mTOR inhibitors (660 patients) and VEGF targeted therapies (2,974 patients). The latter three groups were on phase II/III clinical trials, while the immunotherapy […]

read more

ESMO 2019: First-line avelumab plus axitinib in sarcomatoid kidney cancer – results from JAVELIN Renal 101

Results from the JAVELIN Renal 101 study to evaluate avelumab plus axitinib in untreated sarcomatoid renal cell carcinoma (RCC) were presented at the European Society for Medical Oncology (ESMO) conference in Barcelona over the weekend. Sarcomatoid differentiation can occur in all subtypes of renal cell carcinoma (RCC) and is an aggressive form of RCC. JAVELIN […]

read more

ASCO 2019: Safety and efficacy of immune checkpoint inhibitors in patients with pre-existing autoimmune disorders

This study was presented at the American Society of Clinical Oncology (ASCO) 2019 annual meeting in Chicago last month. The trial looked at 103 patients with a variety of different autoimmune disorders, such as psoriasis (22%), thyroiditis (20%), rheumatoid arthritis (13%), polymyalgia rheumatica (8%), inflammatory bowel disease (6%), multiple sclerosis (3%) and lupus (3%) who […]

read more

Telaglenastat/cabozantinib combination shows early activity in metastatic kidney cancer

Telaglenastat is an oral glutaminase inhibitor and this is the first time it has been administered to humans. Glutaminase is a key enzyme that controls the glutamine pathway that is prominent in renal cell carcinoma (RCC) and important for the tumour to thrive in the body. In pre-clinical models, telaglenastat was found to synergise with […]

read more
Showing all 5 results
  TOP